Company Analysis
Sign in

Cytokinetics, Incorporated (CYTK)

Nasdaq: CYTK · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2003
Full chart Alerts Compare
Grade5.2
◀ Past 5.6● Present 4.4▶ Future 6.0
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

257 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cytokinetics, Incorporated’s names, not what it holds today.

Patents granted
257
257 utility, 1976 to Dec 31, 2025
Granted in 2025
12
Against 10 in 2024 and 2 in 2023
Applications published
199
9 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry23
Pharmaceuticals13
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
CYTOKINETICS, INC. its own name
US, as the owner printed on each patent
257 granted
118 published
Cytokinetics, Inc. its own name
named as the applicant on its applications, in US
0 granted
81 published
Names not counted (1)
CYTOKINETICS INC
No country is printed for it. 0 granted and 12 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 14, 202512,441,691Bicyclic 1,4-diazepanones and therapeutic uses thereofOrganic fine chemistryCYTOKINETICS, INC.
Jul 29, 202512,370,179Methods for treating hypertrophic cardiomyopathyPharmaceuticalsCYTOKINETICS, INC.
May 13, 202512,295,952Methods of treating heart failure with cardiac sarcomere activatorsPharmaceuticalsCYTOKINETICS, INC.
Apr 29, 202512,286,437Cardiac sarcomere inhibitorsOrganic fine chemistryCYTOKINETICS, INC.
Apr 15, 202512,275,741Cardiac sarcomere inhibitorsOrganic fine chemistryCYTOKINETICS, INC.
Apr 15, 202512,275,704Heterocyclic compounds and their usesPharmaceuticalsCYTOKINETICS, INC.
Apr 1, 202512,264,133Compounds, compositions and methodsOrganic fine chemistryCYTOKINETICS, INC.
Mar 11, 202512,247,024Process for preparing aficamtenOrganic fine chemistryCYTOKINETICS, INC.
Feb 11, 202512,221,417Salt of omecamtiv mecarbil and process for preparing saltPharmaceuticalsCYTOKINETICS, INC.
Jan 14, 202512,194,039Methods of treating heart failure by administering omecamtiv mecarbilPharmaceuticalsCYTOKINETICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0376444HETEROCYCLIC COMPOUNDS AND THEIR USESPharmaceuticalsCytokinetics, Inc.
Sep 25, 20252025/0296916BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOFOrganic fine chemistryCytokinetics, Inc.
Sep 25, 20252025/0295639METHODS FOR TREATING HEART DISEASESPharmaceuticalsCytokinetics, Inc.
Sep 4, 20252025/0276976CARDIAC SARCOMERE INHIBITORSOrganic fine chemistryCytokinetics, Inc.
Aug 14, 20252025/0255862METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORSPharmaceuticalsCytokinetics, Inc.
Jul 31, 20252025/0243163SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTPharmaceuticalsCytokinetics, Inc.
Jun 26, 20252025/0205228METHODS OF TREATING HEART FAILURE BY ADMINISTERING OMECAMTIV MECARBILPharmaceuticalsCytokinetics, Inc.
Jun 5, 20252025/0177357METHODS FOR TREATING HYPERTROPHIC CARDIOMYOPATHYPharmaceuticalsCytokinetics, Inc.
Feb 20, 20252025/0059173CARDIAC SARCOMERE INHIBITORSOrganic fine chemistryCytokinetics, Inc.
Nov 7, 20242024/0368172CARDIAC SARCOMERE INHIBITORSOrganic fine chemistryCytokinetics, Inc. · patent 12,275,741 granted from it
What it applied for, 2024 to 2025: Organic fine chemistry 12 · Pharmaceuticals 11.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CYTK · research, not advice